Avidian Wealth Solutions LLC Purchases 76 Shares of Danaher Co. (NYSE:DHR)

Avidian Wealth Solutions LLC increased its stake in shares of Danaher Co. (NYSE:DHR) by 5.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,558 shares of the conglomerate’s stock after acquiring an additional 76 shares during the quarter. Avidian Wealth Solutions LLC’s holdings in Danaher were worth $361,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of DHR. Wellington Management Group LLP grew its holdings in Danaher by 18.6% during the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Allen Investment Management LLC grew its holdings in Danaher by 1,440.7% during the third quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after buying an additional 1,028,976 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Danaher during the third quarter worth $178,850,000. Alecta Tjanstepension Omsesidigt bought a new stake in Danaher during the fourth quarter worth $161,994,000. Finally, Harris Associates L P grew its holdings in Danaher by 27.7% during the third quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock worth $735,343,000 after buying an additional 642,759 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR traded down $0.57 during trading on Monday, reaching $247.81. 725,346 shares of the company were exchanged, compared to its average volume of 2,744,560. The company’s 50-day moving average is $248.48 and its two-hundred day moving average is $232.60. The company has a market cap of $183.55 billion, a price-to-earnings ratio of 42.10, a P/E/G ratio of 3.82 and a beta of 0.83. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.36 EPS. Research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were issued a $0.27 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analysts Set New Price Targets

DHR has been the subject of a number of recent analyst reports. TD Cowen upped their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Raymond James upped their price objective on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Barclays upped their price objective on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, KeyCorp upped their price objective on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $267.31.

Insider Buying and Selling at Danaher

In other Danaher news, Director Walter G. Lohr sold 3,289 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the sale, the director now owns 14,129 shares of the company’s stock, valued at approximately $3,548,498.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Walter G. Lohr sold 3,289 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the transaction, the director now owns 14,129 shares in the company, valued at $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold a total of 107,273 shares of company stock valued at $26,813,819 in the last 90 days. Corporate insiders own 10.90% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.